Other languages Xintela AB

Equities

XINT

SE0007756903

Market Closed - Nasdaq Stockholm Other stock markets 08:53:30 13/05/2024 pm IST			5-day change	1st Jan Change
0.249 ^SEK	+0.40%		-2.35%	-8.12%

28/02	Xintela AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
20/02	Xintela Names New Chief Scientific Officer	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Xintela AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Xintela Appoints Lucienne Vonk as Chief Scientific Officer	20/02
Xintela AB Announces First Patient Dosed in It's Clinical Study on Difficult-To-Heal Leg Ulcers	21/12
Xintela Publishes Efficacy Results with EQSTEM from Preclinical Equine OA Study	20/12
Xintela AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	24/11
Xintela's Stem Cell Product, Xstem, Assessed as Safe At All Dose Levels in Knee Osteoarthritis Clinical Study	13/23/13
Xintela AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	30/23/30
Xintela Receives Product Patent in USA for Chondrocyte-Based Products	15/23/15
Xintela Completes XSTEM Dosing at Third and Final Dose Level in Knee Osteoarthritis Clinical Study	22/23/22
Xintela AB Announces Clinical Study with XSTEM for Knee Oeoarthritis Makes Good Progress	01/23/01
Xintela AB Reports Earnings Results for the First Quarter Ended March 31, 2023	25/23/25
Xintela AB Initiates Last Dose Level in Knee Osteoarthritis Study	02/23/02
Xintela Starts Last Dose Level of Xstem in Knee Osteoarthritis Clinical Study	13/23/13
Xintela AB Completes Dosing of XSTEM Second Dose Level in Knee Osteoarthritis Clinical Study	03/23/03
Xintela AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	24/23/24
Xintela and Northx Biologics Sign Collaboration Framework Agreement	14/22/14
Xintela AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	25/22/25
Xintela AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	25/22/25
Xintela Starts Next Dose Level of Xstem in Knee Osteoarthritis Clinical Study	09/22/09
Xintela Completes Dosing of Xstem First Dose Level in Knee Osteoarthritis Clinical Study	30/22/30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Xintela AB

Equities

XINT

SE0007756903

Other languages

Filters